Infections increase the risk of decompensation and death in patients with early alcohol-related liver disease
- PMID: 38486819
- PMCID: PMC10937840
- DOI: 10.1016/j.jhepr.2024.101016
Infections increase the risk of decompensation and death in patients with early alcohol-related liver disease
Erratum in
-
Erratum regarding previously published articles.JHEP Rep. 2025 Feb 17;7(3):101359. doi: 10.1016/j.jhepr.2025.101359. eCollection 2025 Mar. JHEP Rep. 2025. PMID: 40170909 Free PMC article.
Abstract
Background & aims: Infections are frequent in patients with cirrhosis and worsen prognosis. We evaluated the incidence of infections and their impact on decompensation and death in patients with early alcohol-related liver disease (ALD) during long-term follow-up.
Methods: We performed a prospective cohort study of patients in secondary care with a history of excess alcohol intake, no prior decompensation, and with liver biopsies along with clinical investigations conducted at baseline. During follow-up, we reviewed the patients' electronic healthcare records for cases of infections, hospitalizations, transient elastography measurements, decompensations, all-cause mortality, and alcohol intake.
Results: We included 461 patients with a mean age of 56±10 years (76% males; fibrosis stage F0-1/F2/F3-4 = 259/107/93 [56%/23%/20%]). During a median follow-up of 4.5 years (IQR 2.9-6.3), 134 patients (29%) developed a total of 312 infections, most frequently pneumonia (106/312, 34%) and urinary tract infections (57/312, 18%). Excessive alcohol intake during follow-up, smoking ≥30 pack years, MELD score and elevated liver stiffness during follow-up were independent predictors of infections. Patients who developed at least one infection had a significantly increased risk of subsequent decompensation (hazard ratio 4.98, 95% CI 2.47-10.03) and death (hazard ratio 8.24, 95% CI 4.65-14.59). Infections increased the risk of decompensation and death independently of baseline fibrosis stage, age, gender, and MELD score.
Conclusions: Almost one-third of patients with early ALD develop an infection, which worsens their prognosis by increasing the risk of decompensation and death. The risk of infections increases with liver disease severity and ongoing harmful use of alcohol.
Impact and implications: This study reveals that infections significantly worsen the prognosis of patients with early alcohol-related liver disease (ALD), increasing the likelihood of decompensation and death by up to eight times. These findings, pertinent to healthcare providers, researchers, and policymakers, emphasize the importance of early prevention and management of infections in patients with ALD, even those in early stages who may be asymptomatic. It was observed that nearly one-third of patients with early-stage ALD developed infections over 4.5 years, with risk factors including alcohol overuse, smoking, and higher MELD scores. The research underscores the critical need to incorporate these insights into clinical practice and public health policies to improve patient outcomes and mitigate the impact of infections in patients with ALD.
Keywords: Alcoholic liver disease; Cirrhosis; Decompensation; Fibrosis; Prognosis.
© 2024 The Author(s).
Conflict of interest statement
MT: Speaker’s fee for Echosens, Siemens Healthcare, Norgine, Madrigal, Takeda, and Tillotts Pharma. Advisory fee from GE Healthcare, Boehringer Ingelheim, GSK and AstraZeneca. Co-founder and board member for Evido. Board member for Alcohol & Society (non-governmental organisation). AK has received grants from EU Horizon 2020, Novo Nordisk Foundation, Innovationfund Denmark, Danish National Research Foundation, Region of Southern Denmark, and AstraZeneca, receives royalties from Gyldendal as a co-author on a textbook of internal medicine, served as speaker for Novo Nordisk, Norgine, Siemens and Nordic Bioscience, and participated in advisory boards for Norgine, Siemens, Resalis Therapeutics, Boehringer Ingelheim and Novo Nordisk. Research support; Norgine, Siemens, Nordic Bioscience, AstraZeneca, Echosens. Consulting Takeda, Resalis Therapeutics, Zealand Pharma, AlphaSights. Board member and co-founder of Evido. JKH: Speaker’s fee from Norgine. MK: Speaker’s fee from Siemens Healthcare. SJ, SL, DNR, MI, KL, CDH, KT, NT, PA, USJ, SD, HBJ, and TH have nothing to disclose. Please refer to the accompanying ICMJE disclosure forms for further details.
Figures




References
-
- IHME Global Burden of disease. 2019. http://ghdx.healthdata.org/
-
- Piano S., Singh V., Caraceni P., et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology. 2019;156(5):1368–1380 e1310. - PubMed
-
- Arvaniti V., D'Amico G., Fede G., et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139(4):1246–1256. 1256 e1241-1245. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous